Aurora(ACB) Prnewswire·2025-01-23 12:00Core Viewpoint - Aurora Cannabis Inc. has launched its first domestically produced medical cannabis product in Germany, under the brand IndiMed, marking a significant step in the company's expansion in the German market following the country's cannabis decriminalization earlier this year [1][2]. Group 1: Product Launch - The new product, Island Sweet Skunk, is a dried flower sativa with 20% THC and less than 1% CBD, expected to be available on January 27 [2]. - IndiMed is cultivated under GACP and EU-GMP guidelines to ensure pharmaceutical-grade quality, with flowers harvested by hand and tested for purity and active ingredient content [2]. Group 2: Market Positioning - Aurora is one of three facilities licensed to cultivate cannabis in Germany, positioning the company uniquely to offer domestic products from its EU-GMP facility in Leuna [2][4]. - The company emphasizes its expertise in navigating complex European regulatory frameworks and its commitment to innovation, reinforcing its status as a leader in the global medical cannabis industry [3][4]. Group 3: Company Overview - Aurora Cannabis Inc. operates in multiple markets including Canada, Europe, Australia, and South America, with a diverse brand portfolio catering to both medical and consumer markets [5]. - The company is recognized as the world's largest medical cannabis company operating in nationally legal markets, continually setting new global benchmarks [4].